circCYP24A1 promotes Docetaxel resistance in prostate Cancer by Upregulating ALDH1A3

circCYP24A1 promotes Docetaxel resistance in prostate Cancer by Upregulating ALDH1A3

Abstract Background Docetaxel (DTX) is the most widely prescribed first-line chemotherapy for advanced prostate cancer (PCa). Unfortunately, DTX resistance invariably emerges, leading to worse prognosis of PCa. Growing evidence has shown that circRNAs had complex spatiotemporal specificity during th...

Full description

Bibliographic Details
Main Authors: Haoli Yin, Haixiang Qin, Lei Yang, Mengxia Chen, Yang Yang, Wenlong Zhang, Jiange Hao, Qun Lu, Jingyan Shi, Junlong Zhuang, Xuefeng Qiu, Hongqian Guo
Format: Article
Language:English
Published: BMC 2022-07-01
Series:Biomarker Research
Subjects:
Prostate cancer
circCYP24A1
miR-1301-3p
ALDH1A3
Docetaxel resistance
Online Access:https://doi.org/10.1186/s40364-022-00393-1

Internet

https://doi.org/10.1186/s40364-022-00393-1

Similar Items